TORONTO, Oct. 1, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX:
KHRNF)(Frankfurt: A2JMZC), a
vertically integrated medical cannabis leader with core operations
in Latin America and Europe, today announced that Joel Friedman, has resigned as Chief Financial
Officer of the Company for personal reasons. Khiron's board of
directors has appointed Swapan
Kakumanu of RTB LLP to the role of Interim CFO, effective
immediately. Mr. Friedman will remain with Khiron until
October 31, 2021 to provide
Mr. Alvaro Torres, Khiron CEO and
Director, commented: "On behalf of the Board of Directors and the
management team, I would like to thank Joel for his contributions
and leadership to our strong finance team and wish him the best in
his future endeavours."
About RTB and Swapan
RTB LLP (www.rtbllp.ca) is a fractional CFO, controller and
accounting services provider for private, publicly-traded and
non-profit organizations, with a team of accounting professionals
with extensive industry experience. Mr. Kakumanu has more
than 25 years of senior finance and operations experience and has
served at the senior executive management levels, both in public
and private companies, in high growth technology, manufacturing,
blockchain, medical device, and oil field services industries. He
has held senior roles as President, Chief Executive Officer, Chief
Financial Officer, Controller, Company Secretary, and Board Member
for public and private companies.
About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis
company with core operations in Latin
America and Europe.
Leveraging wholly-owned medical health centres and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in
Mexico in 2021. The Company is led
by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
SOURCE Khiron Life Sciences Corp.